Literature DB >> 9011683

St. Jude Medical valve prosthesis: an analysis of long-term outcome and prognostic factors.

L F Debétaz1, P Ruchat, M Hurni, A Fischer, F Stumpe, H Sadeghi, G van Melle, J J Goy.   

Abstract

Between 1979 and 1984, 321 patients received 354 St. Jude Medical prostheses (194 aortic, 94 mitral, 1 tricuspid, and 32 multiple valve replacements). Follow-up was 96% complete (2967 patient-years; mean 9.5 years per patient). Actuarial event-free rates at 10 years and linearized rates (in parentheses) of late complications were as follows: embolism, 85.0% +/- 2.3% (2.3% per patient-year); anticoagulant-related hemorrhage, 74.8% +/- 2.7% (3.3% per patient-year); cerebrovascular accident, 81.8% +/- 2.5% (2.6% per patient-year); prosthesis thrombosis, 98.5% +/- 0.7% (0.1% per patient-year); endocarditis, 97.2% +/- 1.1% (0.4% per patient-year); prosthesis dysfunction, 97.1% +/- 1.0% (0.4% per patient-year); hemolytic anemia, 98.5% +/- 0.7% (0.1% per patient-year); reoperation, 97.4% +/- 1.0% (0.4% per patient-year); overall mortality, 63.3% +/- 2.7% (4.2% per patient-year); and valve-related death (including sudden death), 84.7% +/- 2.2% (1.4% per patient-year). Independent preoperative risk factors were as follows: (1) for embolism, cardiac failure as indication for operation and history of prior systemic embolism; (2) for cerebrovascular accidents, the same two factors and age; (3) for endocarditis, diabetes, chronic alcoholism, and aortic valve replacement; (4) for overall mortality, age, ejection fraction (or cardiac index or cardiothoracic index), chronic alcoholism, and history of systemic embolism; and (5) for valve-related death, chronic alcoholism, degenerative cause of valve disease, and prosthetic diameter 23 mm or smaller. Ninety percent of survivors were in New York Heart Association functional class I or II at the end of follow-up. In conclusion, this study confirms the excellent durability of the St. Jude Medical valve and the remarkable functional benefit for the majority of the patients. However, prosthesis-related complications are still common, particularly for small-diameter prostheses. Outcome is strongly related to the patient's preoperative cardiac condition and to the adequacy of anticoagulation control.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9011683     DOI: 10.1016/S0022-5223(97)70409-4

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Experience with the Edwards MIRA mechanical bileaflet valve in the aortic and mitral positions.

Authors:  Arzum Kale; Ulku Yildiz; Benhur Can; Ozer Kandemir; Hilmi Tokmakoglu; Tevfik Tezcaner; Yaman Zorlutuna
Journal:  Tex Heart Inst J       Date:  2006

2.  Complications of prosthetic heart valves.

Authors:  Jeanne M Vesey; Catherine M Otto
Journal:  Curr Cardiol Rep       Date:  2004-03       Impact factor: 2.931

3.  Management of prosthetic heart valve complications.

Authors:  Sunil Mankad
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.